Fig. 3: LNPs containing piperazine-based lipids deliver mRNA to immune cells.
From: Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
a A top-performing LNP-A10 with PPZ-A10, cholesterol, C18PEG2K and DOPE at a ratio of 35:46.5:2.5:16 was identified and formulated with Cre mRNA. b The diameter (nm), polydispersity index (PDI), and pKa of LNP-A10. c LNP-A10 was injected to Ai14 mice at a dose of 1 mg/kg, and %tdTomato+ cells in liver endothelial cells (ECs), hepatocytes, dendritic cells, Kupffer cells, other immunes and spleen macrophages, spleen dendritic cells and spleen other immunes were quantified after three days. N = 3/group, average + SEM. Source data are provided as a Source Data file. d Biodistribution of LNP-A10 in liver ECs, dendritic cells, Kupffer cells, spleen macrophages and spleen dendritic cells. N = 4/group, average ± SEM. Source data are provided as a Source Data file. e %tdTomato+ cells in liver ECs, hepatocytes, dendritic cells, Kupffer cells and liver other immunes after treatment of LNP-A10 at doses of 1 mg/kg, 0.5 mg/kg, and 0.3 mg/kg. N = 3/group, average ± SEM. Two-way ANOVA, *P = 0.0083; ns: not significant. Source data are provided as a Source Data file. f Normalized GFP MFI in Kupffer cells after treatment of LNP-A10 carrying siGFP and siLuc at a dose of 1 mg/kg. N = 4/group, average ± SEM. Two-way ANOVA, **P = 0.0075. Source data are provided as a Source Data file.
